These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 3903179)

  • 1. Strategies for determining the mechanisms of toxicity.
    Gillette J; Weisburger EK; Kraybill H; Kelsey M
    J Toxicol Clin Toxicol; 1985; 23(1):1-78. PubMed ID: 3903179
    [No Abstract]   [Full Text] [Related]  

  • 2. Epidemiologic considerations in the design of toxicologic studies: an approach to risk assessment in humans.
    Woods JS
    Fed Proc; 1979 Apr; 38(5):1891-6. PubMed ID: 570936
    [No Abstract]   [Full Text] [Related]  

  • 3. [Biochemical approaches to assessing the action of carcinogens on the human body].
    Rubenchik BL
    Vopr Onkol; 1983; 29(10):73-9. PubMed ID: 6356584
    [No Abstract]   [Full Text] [Related]  

  • 4. Carcinogenicity testing of drugs.
    Williams GM; Weisburger JH
    Prog Drug Res; 1985; 29():155-213. PubMed ID: 3911261
    [No Abstract]   [Full Text] [Related]  

  • 5. [Effect of enzyme inducers on biotransformation].
    Ruckpaul K; Rein H
    Z Gesamte Hyg; 1984 Sep; 30(9):482-4. PubMed ID: 6516476
    [No Abstract]   [Full Text] [Related]  

  • 6. Shortcomings of rodent carcinogenicity studies.
    Haseman JK; Huff JE; Moore JA
    Fundam Appl Toxicol; 1983; 3(3):3a-7a. PubMed ID: 6884635
    [No Abstract]   [Full Text] [Related]  

  • 7. 11th Alexander Hollaender course in genetic toxicology University of Bío-Bío, Concepcion, Chile,October 2006. Preface.
    Zamorano-Ponce E
    Mutat Res; 2008; 658(3):153. PubMed ID: 18456543
    [No Abstract]   [Full Text] [Related]  

  • 8. Adaptive responses of the liver to foreign compounds, with special reference to microsomal drug-matabolizing enzymes.
    Wada O; Yano Y
    Rev Environ Health; 1974; 1(4):261-82. PubMed ID: 4617260
    [No Abstract]   [Full Text] [Related]  

  • 9. Flavonoids inhibit genetic toxicity produced by carcinogens in cells expressing CYP1A2 and CYP1A1.
    Lautraite S; Musonda AC; Doehmer J; Edwards GO; Chipman JK
    Mutagenesis; 2002 Jan; 17(1):45-53. PubMed ID: 11752233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strategy of long-term animal testing for quantitative evaluation of chemical carcinogenicity.
    Hayashi Y; Kurokawa Y; Maekawa A; Takahashi M
    Dev Toxicol Environ Sci; 1986; 12():383-91. PubMed ID: 3549239
    [No Abstract]   [Full Text] [Related]  

  • 11. NTP toxicology and carcinogenesis studies of triethanolamine (Cas No. 102-71-6) in B6C3F1 mice (dermal studies).
    National Toxicology Program, Public Health Service, National Institutes of Health, US Department of Health and Human Services
    Natl Toxicol Program Tech Rep Ser; 2004 May; (518):5-163. PubMed ID: 15213765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Metals as possible chemical carcinogens].
    Dieter HH
    Schriftenr Ver Wasser Boden Lufthyg; 1987; 74():205-17. PubMed ID: 3310201
    [No Abstract]   [Full Text] [Related]  

  • 13. Estimation of risks of irreversible, delayed toxicity.
    Hoel DG; Gaylor DW; Kirschstein RL; Saffiotti U; Schneiderman MA
    J Toxicol Environ Health; 1975 Sep; 1(1):133-51. PubMed ID: 810599
    [No Abstract]   [Full Text] [Related]  

  • 14. Carcinogenesis studies design and experimental data interpretation/evaluation at the National Toxicology Program.
    Huff JE; Moore JA
    Prog Clin Biol Res; 1984; 141():43-64. PubMed ID: 6718388
    [No Abstract]   [Full Text] [Related]  

  • 15. Estimation of "safe doses" in carcinogenic experiments.
    Hartley HO; Sielken RL
    J Environ Pathol Toxicol; 1977; 1(2):241-78. PubMed ID: 553133
    [No Abstract]   [Full Text] [Related]  

  • 16. Differentiation of genetic versus epigenetic mechanisms of toxicity and its application to risk assessment.
    Stott WT; Watanabe PG
    Drug Metab Rev; 1982; 13(5):853-73. PubMed ID: 6754312
    [No Abstract]   [Full Text] [Related]  

  • 17. Drug metabolizing enzyme system and heme pathway in hepatocarcinogenesis.
    Vazquez E; Gerez E; Caballero F; Polo C; Batlle A
    Cancer Biochem Biophys; 1999 Jul; 17(1-2):25-34. PubMed ID: 10738899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CYP1A induction and human risk assessment: an evolving tale of in vitro and in vivo studies.
    Ma Q; Lu AY
    Drug Metab Dispos; 2007 Jul; 35(7):1009-16. PubMed ID: 17431034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Modifying effect of environmental chemical factors on the metabolic activation of carcinogens].
    Maĭorova IG; Khudoleĭ VV
    Eksp Onkol; 1988; 10(3):9-14. PubMed ID: 3044775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The 1996 Veylien Henderson Award of the Society of Toxicology of Canada. Current concepts: neutrophils and the activation of carcinogens in the breast and other organs.
    Josephy PD; Coomber BL
    Can J Physiol Pharmacol; 1998; 76(7-8):693-700. PubMed ID: 10030448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.